Compare · IRTC vs WST
IRTC vs WST
Side-by-side comparison of iRhythm Holdings Inc. (IRTC) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRTC and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.22B, about 6.3x IRTC ($3.55B).
- Over the past year, IRTC is down 26.7% and WST is up 40.5% - WST leads by 67.2 points.
- IRTC has been more active in the news (17 items in the past 4 weeks vs 4 for WST).
- IRTC has more recent analyst coverage (25 ratings vs 16 for WST).
- Company
- iRhythm Holdings Inc.
- West Pharmaceutical Services Inc.
- Price
- $108.06+0.66%
- $314.41-0.90%
- Market cap
- $3.55B
- $22.22B
- 1M return
- -8.08%
- +0.26%
- 1Y return
- -26.69%
- +40.47%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 17
- 4
- Recent ratings
- 25
- 16
iRhythm Holdings Inc.
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest IRTC
- iRhythm Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Risk Officer Shrishrimal Sumi was granted 133 shares and sold $185,652 worth of shares (1,716 units at $108.19), decreasing direct ownership by 4% to 40,287 units (SEC Form 4) to satisfy tax liability
- Chief Accounting Officer Rosenbaum Marc Wade was granted 178 shares and sold $78,870 worth of shares (729 units at $108.19), decreasing direct ownership by 3% to 16,155 units (SEC Form 4) to cover withholding tax
- CHIEF MED/SCI OFCR EVP ADVTECH Turakhia Minang was granted 137 shares, increasing direct ownership by 0.25% to 55,043 units (SEC Form 4)
- CHIEF COMM & PRODUCT OFFICER Patterson Chad was granted 177 shares, increasing direct ownership by 0.30% to 58,341 units (SEC Form 4)
- EVP, Strategy & Corp Devt Freeman Sean Clinton was granted 273 shares, increasing direct ownership by 2% to 14,559 units (SEC Form 4)
- President and CEO Blackford Quentin S. was granted 178 shares, increasing direct ownership by 0.09% to 204,333 units (SEC Form 4)
- Director Bairey Merz Cathleen Noel was granted 1,573 shares, increasing direct ownership by 18% to 10,546 units (SEC Form 4)
- Director Bodaken Bruce G. was granted 1,573 shares, increasing direct ownership by 12% to 14,211 units (SEC Form 4)
- Director Ling Karen was granted 1,573 shares, increasing direct ownership by 16% to 11,141 units (SEC Form 4)
Latest WST
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)
- Director Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)